The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009, an investigational oral therapy being developed by Inhibikase Therapeutics to slow or stop disease progression.
“We are pleased to begin dosing patients in our Phase 1b study,” Milton Werner, PhD, Inhibikase‘s president and CEO, said in a press release.
Looks promising. Thank you for sharing.
It's moving to a Phase 2 randomized, double-blind, 12-week dosing trial assessing safety & tolerability in untreated
Anyone participating in the Buntanetap Phase 3 trial?
Phase 3 Positive Topline Results for Tavapadon It seems to me that the Parkinson's research is almost zero Free Webinar: “Zhittya's Parkinson's Disease Research Study: 6-Month Patient Follow-Up Report”
Medium-Dose Lithium May Hit Parkinson Disease Targets...
